Geopolitical crises, volatile energy prices, rising interest rates: The German M&A market is navigating unprecedented uncertainty. The much-anticipated “bounce back” has failed to materialise, leaving deal makers facing significant valuation gaps and exceptional risk.
In his latest article for Chambers & Partners, Daniel Fehling from GSK Stockmann explores why Material Adverse Change (MAC) clauses are back in the spotlight and why they function more like options than insurance policies. He breaks down the asymmetric risk allocation between buyers and sellers and shares practical guidance on drafting geopolitical MAC clauses that actually work.
Read the full article here: https://chambers.com/content/item/7405
